<p>Arrowhead Pharmaceuticals, Inc.（納斯達克股票代碼：ARWR - 獲取免費報告）內部人員 Tracie Oliver 在 7 月 2 日星期二的交易中出售了 9,394 股公司股票。這些股票的平均價格為 25.28 美元，總交易額為 237,480.32 美元。交易結束後，該內部人員現在直接持有公司股票 127,107 股，價值約 3,213,264.96 美元。該銷售交易已在提交給證券交易委員會的法律文件中披露，可以通過 SEC 網站查看。</p>
<h2>Arrowhead Pharmaceuticals 股價表現</h2>
<ul>
<li>想在生物技術領域獲得多元化上漲？看看 LABU</li>
</ul>
<p>納斯達克股票代碼 ARWR 週三在午盤交易中下跌 0.15 美元，至 25.07 美元。該股交易量為 360,710 股，相比平均交易量 1,325,371 股。Arrowhead Pharmaceuticals, Inc.一年內最低股價為 20.67 美元，最高股價為 39.83 美元。該股市值為 31.1 億美元，市盈率為-5.90，貝塔係數為 0.94。該公司的 50 天簡單移動平均價格為 24.49 美元，200 天簡單移動平均價格為 28.33 美元。</p>
<p>Arrowhead Pharmaceuticals（納斯達克股票代碼 ARWR - 獲取免費報告）最近公佈了截至 5 月 9 日星期四的季度財報。這家生物技術公司報告該季度每股虧損 1.02 美元，低於市場預期的每股虧損 0.06 美元。Arrowhead Pharmaceuticals 的淨資產收益率為-140.72%，淨利潤率為-163.32%。去年同期，該公司每股收益為 0.45 美元。該季度公司的營收同比下降了 100.0%。股票研究分析師平均預計，Arrowhead Pharmaceuticals, Inc.本財年每股盈利將達到-3.05 美元。</p>
<h2>對 Arrowhead Pharmaceuticals 的對沖基金看法</h2>
<p>最近，對沖基金調整了他們對該股票的持股。O Shaughnessy Asset Management LLC 在第三季度新建了一份 Arrowhead Pharmaceuticals 的持倉，價值 25.7 萬美元。Qube Research &amp; Technologies Ltd 在第三季度將其 Arrowhead Pharmaceuticals 的持倉增加了 98.2%。Qube Research &amp; Technologies Ltd 現在擁有 71,558 股該生物技術公司股票，價值 192.3 萬美元，較之前增加了 35,463 股。Glenmede Trust Co. NA 在第三季度將其 Arrowhead Pharmaceuticals 的持股增加了 68.6%。Glenmede Trust Co. NA 現在擁有 16,905 股該生物技術公司股票，價值 45.4 萬美元，較之前增加了 6,876 股。Seven Eight Capital LP 在第三季度將其 Arrowhead Pharmaceuticals 的持股增加了 92.6%。Seven Eight Capital LP 現在擁有 24,474 股該生物技術公司股票，價值 65.8 萬美元，較之前增加了 11,764 股。最後，Sectoral Asset Management Inc.在第三季度將其 Arrowhead Pharmaceuticals 的持股增加了 9.5%。Sectoral Asset Management Inc.現在擁有 157,552 股該生物技術公司股票，價值 423.3 萬美元，較之前增加了 13,630 股。該股票的 62.61% 由機構投資者和對沖基金持有。</p>
<h2>分析師設定新的股價目標</h2>
<p>一些研究分析師對該股票發表了評論。摩根大通將 Arrowhead Pharmaceuticals 的目標股價從 36.00 美元降至 27.00 美元，並在 5 月 13 日星期一的研究報告中為該公司設定了 “持平” 評級。Chardan Capital 重申了對 Arrowhead Pharmaceuticals 的 “買入” 評級，並在 6 月 26 日星期三的研究報告中設定了 60.00 美元的目標股價。HC Wainwright 重申了對 Arrowhead Pharmaceuticals 的 “買入” 評級，並在 6 月 11 日星期二的研究報告中設定了 90.00 美元的目標股價。StockNews.com 在一份研究報告中將 Arrowhead Pharmaceuticals 的評級提升至 “賣出”。最後，Cantor Fitzgerald 在 6 月 20 日星期四的研究報告中重申了對 Arrowhead Pharmaceuticals 的 “超重” 評級。一位分析師對該股票進行了賣出評級，三位分析師給予持有評級，七位分析師給予買入評級。根據 MarketBeat 的數據，該股目前的平均評級為 “中等買入”，並且有一個 47.89 美元的共識目標股價。</p>
<p><strong>獲取我們對 Arrowhead Pharmaceuticals 的最新研究報告</strong></p>
<h2>Arrowhead Pharmaceuticals 公司簡介（獲取免費報告）</h2>
<p>Arrowhead Pharmaceuticals, Inc.致力於開發治療美國難治性疾病的藥物。該公司的產品管線包括 Plozasiran，目前處於 2b 期和一項 3 期臨牀試驗階段，用於治療高甘油三酯血癥、混合性脂質代謝異常和乳糜微粒血癥綜合徵；Zodasiran 目前處於 2b 臨牀試驗階段，用於治療脂質代謝異常和高甘油三酯血癥；ARO-PNPLA3 目前處於 1 期臨牀試驗階段，用於治療非酒精性脂肪肝患者；ARO-RAGE 目前處於 1/2a 期臨牀試驗階段，用於治療炎症性肺部疾病；ARO-MUC5AC 目前處於 1/2a 期臨牀試驗階段，用於治療黏液阻塞性肺部疾病。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們比 Arrowhead Pharmaceuticals 更喜歡的股票</li>
<li>為何特別股息對收入投資者來説是一個令人愉快的驚喜</li>
<li>AbbVie 股票：投資者購買的完美機會</li>
<li>哪些華爾街分析師最準確？</li>
<li>忘記 NVIDIA：超微電腦股票在動量方面領先</li>
<li>如何計算股票利潤</li>
<li>GitLab 股票反彈：其復甦內幕報道</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 操作替換拜登已啓動（來自自由港協會）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5"/></p>
<h2>現在是否值得投資箭頭製藥公司（Arrowhead Pharmaceuticals）1,000 美元？</h2>
<p>在考慮投資箭頭製藥公司之前，您可能想要聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在應該購買的股票... 而箭頭製藥公司並不在名單上。</p>
<p>儘管箭頭製藥公司目前在分析師中擁有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

箭頭制藥

<p>箭頭製藥公司內部人士 Tracie Oliver 出售了 9,394 股股票，總交易額為 $237,480.32。該公司股價一直在波動，分析師已經為該股設定了一個價格目標。這屬於與商業相關的信息</p>

<p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider Tracie Oliver sold 9,394 shares of the business's stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total transaction of $237,480.32. Following the transaction, the insider now directly owns 127,107 shares of the company's stock, valued at approximately $3,213,264.96. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc.（納斯達克股票代碼：ARWR - 獲取免費報告）內部人員 Tracie Oliver 在 7 月 2 日星期二的交易中出售了 9,394 股公司股票。這些股票的平均價格為 25.28 美元，總交易額為 237,480.32 美元。交易結束後，該內部人員現在直接持有公司股票 127,107 股，價值約 3,213,264.96 美元。該銷售交易已在提交給證券交易委員會的法律文件中披露，可以通過 SEC 網站查看。</p>
</div><h2>Arrowhead Pharmaceuticals Price Performance</h2>
<ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 股價表現</h2>
<ul>
<li>想在生物技術領域獲得多元化上漲？看看 LABU</li>
</ul>
</div><p>NASDAQ:ARWR traded down $0.15 during midday trading on Wednesday, reaching $25.07. The stock had a trading volume of 360,710 shares, compared to its average volume of 1,325,371. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $20.67 and a 1-year high of $39.83. The stock has a market capitalization of $3.11 billion, a P/E ratio of -5.90 and a beta of 0.94. The firm's fifty day simple moving average is $24.49 and its 200-day simple moving average is $28.33.</p>
<div class="lb-trans"><p>納斯達克股票代碼 ARWR 週三在午盤交易中下跌 0.15 美元，至 25.07 美元。該股交易量為 360,710 股，相比平均交易量 1,325,371 股。Arrowhead Pharmaceuticals, Inc.一年內最低股價為 20.67 美元，最高股價為 39.83 美元。該股市值為 31.1 億美元，市盈率為-5.90，貝塔係數為 0.94。該公司的 50 天簡單移動平均價格為 24.49 美元，200 天簡單移動平均價格為 28.33 美元。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same period last year, the business posted $0.45 EPS. The company's revenue for the quarter was down 100.0% on a year-over-year basis. On average, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.05 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals（納斯達克股票代碼 ARWR - 獲取免費報告）最近公佈了截至 5 月 9 日星期四的季度財報。這家生物技術公司報告該季度每股虧損 1.02 美元，低於市場預期的每股虧損 0.06 美元。Arrowhead Pharmaceuticals 的淨資產收益率為-140.72%，淨利潤率為-163.32%。去年同期，該公司每股收益為 0.45 美元。該季度公司的營收同比下降了 100.0%。股票研究分析師平均預計，Arrowhead Pharmaceuticals, Inc.本財年每股盈利將達到-3.05 美元。</p>
</div><h2>Hedge Funds Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Arrowhead Pharmaceuticals 的對沖基金看法</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. O Shaughnessy Asset Management LLC bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $257,000. Qube Research &amp; Technologies Ltd grew its position in shares of Arrowhead Pharmaceuticals by 98.2% during the 3rd quarter. Qube Research &amp; Technologies Ltd now owns 71,558 shares of the biotechnology company's stock worth $1,923,000 after buying an additional 35,463 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Arrowhead Pharmaceuticals by 68.6% during the third quarter. Glenmede Trust Co. NA now owns 16,905 shares of the biotechnology company's stock worth $454,000 after buying an additional 6,876 shares during the last quarter. Seven Eight Capital LP lifted its holdings in Arrowhead Pharmaceuticals by 92.6% in the third quarter. Seven Eight Capital LP now owns 24,474 shares of the biotechnology company's stock valued at $658,000 after buying an additional 11,764 shares during the period. Finally, Sectoral Asset Management Inc. boosted its stake in Arrowhead Pharmaceuticals by 9.5% in the third quarter. Sectoral Asset Management Inc. now owns 157,552 shares of the biotechnology company's stock valued at $4,233,000 after acquiring an additional 13,630 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近，對沖基金調整了他們對該股票的持股。O Shaughnessy Asset Management LLC 在第三季度新建了一份 Arrowhead Pharmaceuticals 的持倉，價值 25.7 萬美元。Qube Research &amp; Technologies Ltd 在第三季度將其 Arrowhead Pharmaceuticals 的持倉增加了 98.2%。Qube Research &amp; Technologies Ltd 現在擁有 71,558 股該生物技術公司股票，價值 192.3 萬美元，較之前增加了 35,463 股。Glenmede Trust Co. NA 在第三季度將其 Arrowhead Pharmaceuticals 的持股增加了 68.6%。Glenmede Trust Co. NA 現在擁有 16,905 股該生物技術公司股票，價值 45.4 萬美元，較之前增加了 6,876 股。Seven Eight Capital LP 在第三季度將其 Arrowhead Pharmaceuticals 的持股增加了 92.6%。Seven Eight Capital LP 現在擁有 24,474 股該生物技術公司股票，價值 65.8 萬美元，較之前增加了 11,764 股。最後，Sectoral Asset Management Inc.在第三季度將其 Arrowhead Pharmaceuticals 的持股增加了 9.5%。Sectoral Asset Management Inc.現在擁有 157,552 股該生物技術公司股票，價值 423.3 萬美元，較之前增加了 13,630 股。該股票的 62.61% 由機構投資者和對沖基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的股價目標</h2>
</div><p>Several research analysts have commented on the stock. Morgan Stanley decreased their target price on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an &#34;equal weight&#34; rating for the company in a research report on Monday, May 13th. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, June 26th. HC Wainwright reissued a &#34;buy&#34; rating and set a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, June 11th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a &#34;sell&#34; rating in a research report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Arrowhead Pharmaceuticals in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $47.89.</p>
<div class="lb-trans"><p>一些研究分析師對該股票發表了評論。摩根大通將 Arrowhead Pharmaceuticals 的目標股價從 36.00 美元降至 27.00 美元，並在 5 月 13 日星期一的研究報告中為該公司設定了 “持平” 評級。Chardan Capital 重申了對 Arrowhead Pharmaceuticals 的 “買入” 評級，並在 6 月 26 日星期三的研究報告中設定了 60.00 美元的目標股價。HC Wainwright 重申了對 Arrowhead Pharmaceuticals 的 “買入” 評級，並在 6 月 11 日星期二的研究報告中設定了 90.00 美元的目標股價。StockNews.com 在一份研究報告中將 Arrowhead Pharmaceuticals 的評級提升至 “賣出”。最後，Cantor Fitzgerald 在 6 月 20 日星期四的研究報告中重申了對 Arrowhead Pharmaceuticals 的 “超重” 評級。一位分析師對該股票進行了賣出評級，三位分析師給予持有評級，七位分析師給予買入評級。根據 MarketBeat 的數據，該股目前的平均評級為 “中等買入”，並且有一個 47.89 美元的共識目標股價。</p>
</div><p><strong>Get Our Latest Research Report on Arrowhead Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Arrowhead Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>Arrowhead Pharmaceuticals Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 公司簡介（獲取免費報告）</h2>
</div><p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc.致力於開發治療美國難治性疾病的藥物。該公司的產品管線包括 Plozasiran，目前處於 2b 期和一項 3 期臨牀試驗階段，用於治療高甘油三酯血癥、混合性脂質代謝異常和乳糜微粒血癥綜合徵；Zodasiran 目前處於 2b 臨牀試驗階段，用於治療脂質代謝異常和高甘油三酯血癥；ARO-PNPLA3 目前處於 1 期臨牀試驗階段，用於治療非酒精性脂肪肝患者；ARO-RAGE 目前處於 1/2a 期臨牀試驗階段，用於治療炎症性肺部疾病；ARO-MUC5AC 目前處於 1/2a 期臨牀試驗階段，用於治療黏液阻塞性肺部疾病。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Forget NVIDIA: Super Micro Computer Stock Leads in Momentum</li>
<li>How to Calculate Stock Profit</li>
<li>GitLab Stock Rebounds: The Inside Story of Its Comeback</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>五隻我們比 Arrowhead Pharmaceuticals 更喜歡的股票</li>
<li>為何特別股息對收入投資者來説是一個令人愉快的驚喜</li>
<li>AbbVie 股票：投資者購買的完美機會</li>
<li>哪些華爾街分析師最準確？</li>
<li>忘記 NVIDIA：超微電腦股票在動量方面領先</li>
<li>如何計算股票利潤</li>
<li>GitLab 股票反彈：其復甦內幕報道</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Operation Replace Biden is a Go (From The Freeport Society)(Ad)</p>
<div class="lb-trans"><p>→ 操作替換拜登已啓動（來自自由港協會）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8589&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Arrowhead Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資箭頭製藥公司（Arrowhead Pharmaceuticals）1,000 美元？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資箭頭製藥公司之前，您可能想要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在應該購買的股票... 而箭頭製藥公司並不在名單上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管箭頭製藥公司目前在分析師中擁有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

箭頭製藥公司（納斯達克：ARWR）的內部人士 Tracie Oliver 出售了 9,394 股股票